Publication Name	World Journal of Gastroenterology
Manuscript ID	5557
Country	Greece

Received	2013-09-15 20:29
Peer-Review Started	2013-09-16 10:45
To Make the First Decision	2013-10-14 21:21
Return for Revision	2013-10-15 20:00
Revised	2013-10-29 15:42
Second Decision	2013-11-18 20:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-11-19 11:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-11-27 00:22
Typeset the Manuscript	2013-12-16 11:55
Publish the Manuscript Online	2014-01-14 20:11

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation
Manuscript Source	Invited Manuscript
All Author List	Evangelos Cholongitas and George V Papatheodoridis
Funding Agency and Grant Number
Corresponding Author	Dr. Evangelos Cholongitas, Lecturer of Internal Medicine, the 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 49, Konstantinopoleos Street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Key Words	Hepatitis B virus; Liver transplantation; Hepatitis B virus immunoglobulin; Antivirals; Lamivudine; Adefovir; Entecavir; Tenofovir; Telbivudine; Resistance
Core Tip	In the present review the current knowledge on the management of hepatitis B virus (HBV) infection before and after liver transplantation is updated. There is no doubt that all HBV patients with decompensated cirrhosis should be treated with potent anti-HBV agents with high genetic barrier (i.e., entecavir or tenofovir). After liver transplantation, the combination of HBV immunoglobulin (HBIG) (at least for a certain period) and entecavir or tenofovir currently appears to be the most reasonable approach, while HBIG-free antiviral prophylaxis cannot be excluded in the future, particularly in patients with low risk of recurrence.
Publish Date	2014-01-14 20:11
Citation	Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197
URL	http://www.wjgnet.com/1007-9327/full/v19/i48/9189.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i48.9189

Full Article (PDF)	WJG-19-9189.pdf
Manuscript File	5557-Review.doc
Answering Reviewers	5557-Answering reviews.pdf
Copyright License Agreement	5557-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5557-Language certificate.pdf
Peer-review Report	5557-Peer review(s).pdf
Scientific Editor Work List	5557-Scientific editor work list.doc